Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 12, 2002 - Issue 2
Submit an article Journal homepage
45
Views
15
CrossRef citations to date
0
Altmetric
Miscellaneous

Echinocandins - an update

Hugo Vanden Bossche Steenweg op Gierle, 68, B2300 Turnhout, Belgium. [email protected]
Pages 151-167 | Published online: 25 Feb 2005

Bibliography

  • ODDS FC: Pathogenic fungi in the 21sL century. Trends Nlicrobiol. (2000) 8:200–201.
  • WARNOCK DW: Introduction to the management of fungal infection in the compromised host. In: Fungal Infection in the Compromised patient, 2'd edition. Warnock DW, Richardson MD (Eds.), John Wiley & Sons, Chichester, UK (1990):23–53.
  • BECK-SAGU CM, JARWIS WR: Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980–1990.1 Infect. Dis. (1993) 167:1247–1251.
  • KIBBLER CC: Epidemiology of fungal infections. In: Principles and Practice of Clinical Mycology Kibbler CC, Mackenzie DWR, Odds FC (Eds.), John Wiley & Sons, Chichester, UK. (1996):13–21.
  • AMPEL NM: Emerging disease issues and fungal pathogens associated with HIV infection. Emerg. Infect. Dis. (1996) 2:109–116.
  • CHIOU CC, GROLL AH, GONZALEZ CE etal.: Esophageal candidiasis in pediatric acquired immunodeficiency syndrome: clinical manifestations and risk factors. Pediatr. Infect. Dis. J. (2000) 19:729–734.
  • CHOCARRO MARTINEZ A, GALINDO F, RUIZ-IRASTORZA G, GONZALEZ LOPEZ A: Risk factors for esophageal candidiasis. Eur. I Chi]. Microbial. Infect. Dis. (2000) 19:96–100.
  • PFALLER MA, JONES RN, MESSER SA, EDMOND MB, WENZEL RP: National surveillance of nocosomial blood stream infection due to Candida albicans frequency of occurrence and antifungal susceptibility in the SCOPE program. Diagn. Microbial. Infect. Dis. (1998) 31:327–332.
  • VISCOLI C, GIRMENIA C, MARINUS A etal.: Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Chi]. Infect. Dis. (1999) 28:1071–1079.
  • LATGE J-P: Aspergillus furnigatus and aspergillosis. CBI]. Microbial. Rev (1999) 12:310–350.
  • •A thorough review on aspergillosis.
  • FANOS V, CATALDI L: Amphotericin B- nephrotoxicity: a review.Chernother. (2000) 12:463–470.
  • •A comprehensive review of amphotericin's adverse reactions.
  • VANDEN BOSSCHE H: Chemotherapy ofhuman fungal infections. In: Modern Selective Fungicides. Lyr H (Ed), Gustav Fisher Verlag, Jena, Germany. (1995):431–484.
  • VERMES A, GUCHELAAR HJ, J: Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J. Antlinicrob. Chernother. (2000) 46:171–179.
  • •A good update of flucytosine's properties.
  • SHEEHAN DJ, HITCHCOCK CA, SIBLEY CM: Current and emerging azole antifungal agents. CBI]. Microbial. Rev (1999) 12:40–79.
  • KAUFFMAN CA, CARVER PL: Antifungal agents in the 1990s. Current status and future developments. Drugs (1997) 53:539–549.
  • HAROUSSEAU JL, DEKKER AW, STAMATOULLAS-BASTARD A et al.: oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob. Agents Chernother. (2000) 44:1887–1893.
  • ODDS FC: Antifungal therapy. In: Principles and Practice of Clinical Mycology Kibbler CC, Mackenzie DWR, Odds FC (Eds.), John Wiley & Sons, Chichester, UK. (1996):35–48.
  • •A comprehensive review of the present and future antifungal agents.
  • STEVENS DA, HOLMBERG K: to antifungal drugs: Current status and clinical implications. Curr. Opin Antidrifec. Investig. Drugs. (1999) 1:306–317.
  • ESPINEL-INGROFF A, WARNOCK DW, VAQUEZ JA, ARTHINGTON-SKAGGS BA: In vitro antifungal susceptibilty methods and clinical implications of antifungal resistance. Med. Mycol. (2000) 38\(Suppl. 1):293–304.
  • MARICHAL P: Mechanisms of resistance to azole antifungal compounds. Curr. Opin. Ther. Antidrifec. Irivestig. Drugs. (1999) 1:318–333.
  • •Good review of the mechanisms of antifungal resistance.
  • WALSH TJ, VIVIANI M-A, E et al.: New targets and delivery systems for antifungal therapy. Med. Mycol. (2000) 38\(Suppl. 1):335–347.
  • GROLL AH, WALSH TJ: MK-0991 Merck & Co. Curr. Opin. Anti-infect. Invest. Drugs (1999) 1:334–345.
  • ••Excellent overview of the properties ofcaspofungin (MK-0991).
  • BENZ F, KNUSEL F, NEUSCH J et al.: Stoffwechsel Produkte von Mikroorganismen. Echinocandin B, emn neuartiges Polypetid- Antibiotikum aus Aspergillus nidularis var, echinulatus: Isolierung und Bausteine. Hely. China. Acta (1974) 57:2459–2477.
  • •One of the first papers on echinocandin B.
  • HAMMOND ML: Chemical and structure-activity studies of the echinocandin lipopeptides. In: Cutaneous Antifungal Agents. Rippon JW, Fromtling RA (Eds), Marcel Dekker, Inc., New York, USA (1993):395–420.
  • MIZUNO K, YAGI A, SATOI S, TAKADA M, HAYASHI M: Studies on aculeacin. I. Isolation and characterization of aculeacin A. j Aritibiot. (Tokyo) (1977) 30:297–302.
  • DEBONO M, ABBOTT BJ, TURNER JR et al.: Synthesis and evaluation of LY121019, a member of a series of semisynthetic analogues of the antifungal lipopeptide echinocandin B. Ann. NY Acad. Sc. (1988) 544:152–167.
  • GORDEE RS, ZECKNER DJ, HOWARDLC, ALBORN WE JR DEBONO M: Anti- Candida activity and toxicology of LY121019, a novel semisynthetic polypeptide antifungal antibiotic. Ann. NY Acad. Sc. (1988) 544:294–309.
  • PFALLER M. GORDEE R, GERARDEN T, YU M, WENZEL R: Fungicidal activity of cilofungin (LY121019) alone and in with anticapsin or other antifungal agents. Eur. I Chia. 11/licrobiol. Infect. Dis. (1989) 8:564–567.
  • ODDS FC: Activity of cilofungin (LY121019) against Candida species in vitro. j Aritimicrob. Chemother (1988) 22:891–897.
  • BARTIZAL K, ABRUZZO GK, SCHMATZ DM: Biological activity of the pneumocandins. In: Cutaneous Antifungal Agents. Rippon JW, Fromtling RA (Eds), Marcel Dekker, Inc. New York, USA (1993):421–455.
  • ••An excellent review of the biologicalproperties of the first series of pneumocandins.
  • GORDEE RS, ZECKNER DJ, ELLIS LF, THAKKAR AL, HOWARD LC: In vitro and in vivo anti- Canctida activity and toxicology of LY121019.j Aritibiot. (Tokyo) (1984) 37:1054–1065.
  • BEAULIEU D, TANG J, ZECKNER DJ, PARR TR JR: Correlation of cilofungin in vivo efficacy with its activity against Aspergillus fumigatus (1,3)-P-D-glucan synthase. FEMS Microbial. Lett. (1993) 108:133–137.
  • GROLL AH, WALSH TJ: Potential new antifungal agents. Curr. Opin. Infect. Dis. (1997) 10:449–458.
  • HAWSER S: LY-303366 Eli Lilly & Co. Curr Opin. Anti-infect. Invest. Drugs (1999) 1:353–360.
  • ••Overview of the properties of LY-303366.
  • KRISHNARAO TV, GALGIANI JN: Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991 and fluconazole against Caridida species and Cryptococcus rieoformaris. Aritimicrob. Agents. Chemother (1997) 41:1957–1960.
  • ESPINEL-INGROFF A: Comparison of invitro activities of the new triazole 5CH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. j CBI]. Microbial. (1998) 36:2950–2956.
  • •The in vitro characterisation of caspofungin and anidulafungin is described.
  • GREEN LJ, MARDER P, MANN LL, CHIO L-C, CURRENT WL: LY303366 exhibits rapid and potent fungicidal activity in flow cytometric assays of yeast viability. Aritimicrob. Agents. Chemother (1999) 43:830–835.
  • PETRAITIS V, PETRAITIENE R, GROLLA et al.: Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. Antimicrob. Agents Chemother. (2001) 45:471–479.
  • GROLL AH, MICKIENE D, R etal.: Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob. Agents. Chemother. (2001) 45:2845–2855.
  • VERWEIJ PE, OAKLEY KL, MORRISSEY J, MORRISSEY G, DENNING DW: Efficacy of LY303366 against amphotericin B-susceptible and - resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Aritimicrob. Agents Chemother. (1998) 42:873–878.
  • BARTLETT MS, CURRENT WL, GOHEEN MP et al.: Semisynthetic echinocandins affect cell wall deposition of Prieumocystis carinii in vitro and in vivo. Aritimicrob. Agents Chemother. (1996) 40:1811–1816.
  • ZORNES LL, STRATFORD RE: Development of a plasma high-performance liquid chromatography assay for LY303366, a lipopeptide antifungal agent and its application in a dog pharmacokinetic study. Chromtogr. Biomed. Li. AppL (1997) 695:381–387.
  • IWAMOTO T, FUJIE A, SAKAMOTO K et al.: WF11899A, B and C, novel antifungal lipopeptides. I. Taxonomy, fermentation, isolation and physico-chemical properties. _J. Antibiot. (Tokyo) (1994) 47:1084–1091.
  • IWAMOTO T, FUJIE A, NITTA K, HASHIMOTO S, OKUHARA M, KOHSAKA M: WF11899A, B and C, novel antifungal lipopeptides. II. Biological properties. j Aritibiot. (Tokyo) (1994) 47:1092–1097.
  • SCHWARTZ RE: Cell wall active antifungal agents. Expert Opin. Ther. Patents (2001) 11(10:1761–1772.
  • FUJIE A, IWAMOTO T, SATO B et al.: FR131535, a novel water-soluble echinocandin-like lipopeptide: synthesis and biological properties. Bioorg. Med. Chem. (2001) 11:399–402.
  • FURUTA T, MURAMATSU H, FUJIE A, FUJIHIRA S, ABUDULLAH NR, KOJIMA S: Therapeutic effects of water echinocandin compounds on Prieumacystis pneumonia in mice. Antimicrob.Agerris Chemother (1998) 42:37–39.
  • TOMISHIMA M, OHM H, YAMADA A et al.: FK463, a novel water-soluble echinocandin lipopeptide: synthesis and antifungal activity. j Antibiot. (Tokyo) (1999) 52:674–676.
  • TAWARA S, IKEDA F, MAKI K et al.: hivitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob. Agents Chemother (2000) 44:57–62.
  • •The in vitro characterisation of micafungin is described.
  • UCHIDA K, NISHIYAMA Y, YOKOTA N, YAMAGUCHI H: In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens.j Antibiat. (Tokyo) (2000) 53:1175–1181.
  • MULLER FM, KURZAI O, HACKER J, FROSCH M, MUHLSCHLEGEL F: Effect of growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis. j Antimicrob. Chemother (2001) 48:713–715.
  • MIKAMO H, SATO Y, TAMAYA T: In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. j. Antimicrob. Chemother. (2000) 46:485–487.
  • CHIOU CC, MAVROGIORGOS N, TILLEM E, HECTOR R, WALSH TJ: Synergy, pharmacodynamics and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob. Agents Chemother. (2001) 45:3310–3321.
  • •Excellent paper on the synergy between nildtomycin Z and micafungin.
  • GROLL AH, MICKIENE D, PETRAITIS et al.: Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob. Agents Chemother. (2001) 45:3322–3327.
  • IKEDA F, WAKAI Y, MATSUMOTO S et al.: Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob. Agents Chemother (2000) 44:614–618.
  • •This paper provides a good overview of the broad in vivo activity of micafungin.
  • MAESAKI S, HOSSAIN MA, MIYAZAKI Y, TOMONO K, TASHIRO T, KOHNO S: Efficacy of FK463, a (1,3) D glucan synthase inhibitor, in disseminated azole-resistant Candida albicans infection in mice. Antimicrob. Agents Chernother. (2000) 44:1728–1730.
  • MATSUMOTO S, WAKAI Y, NAKAI T et al.: Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis. Antimicrob. Agents Chemother (2000) 44:619–621.
  • ITO M, NOZU R, KURAMOCHI T et al.: Prophylactic effect of FK463, a novel antifungal lipopeptide, against Prieumacystis carinii infection in mice. Antimicrob. Agents Chemother (2000) 44:2259–2262.
  • PETTENGELL K, MYNHARDT J, KLUYTS T, SONI P: A multicenter study to determine the minimal effective dose of FK463 for the treatment of esophageal candidiasis in HIV-positive patients. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (1999) Abstract No. 1421.
  • SCHWARTZ RE, GIACOBBE RA, BLAND JA, MONAGHAN RL: L-671,329, a new antifungal agent. I. Fermentation and isolation.j Antibiat. (To/do) (1989) 42:163–167.
  • SCHWARTZ RE, MASUREKAR PS, WHITE RF: Discovery, production process development and isolation of pneumocandin B0. In: Cutaneous Antifurigal Agents. Rippon JW, Fromtling RA (Eds), Marcel Dekker, Inc., New York, USA: (1993)375–393.
  • ••Good monograph on the discovery of thepneumocandins.
  • SCHMATZ DM, ROMANCHECK MA, PITARELLI LA et al.: Treatment of Prieumacystis carinii pneumonia with 1,3-13-glucan synthesis inhibitors. Proc. Nati Acad. Sci. USA (1990) 87:5950–5954.
  • GROLL AH, WALSH TJ: Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin. Investig. Drugs. (2001) 1545–1558.
  • ••An excellent review on the properties ofcaspofungin.
  • BOUFFARD FA, ZAMBIAS RA, DROPINSKI JF et al.: Synthesis and antifungal activity of novel cationic pneumocandin Bo derivatives.j Med. Chem. (1994) 37:222–225.
  • GILL CJ, PACHOLOK C, LYNCH L, KROPP H: In vitro evaluation of the antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373. Antimicrob. Agents Chemother. (1995) 39:1070–1076.
  • ABRUZZO GK, FLATTERY AM, GILL CJ et al.: Evaluation of water-soluble pneumocandin analogs L-733560, L-705589 and L-731373 with mouse models of disseminated aspergillosis and cryptococcosis. Antimicrob. Agents Chemother. (1995) 39:1077–1081.
  • •Original report on the synthesis of the Merck echinocandins.
  • GEORGOPAPADAKOU NH: Update on antifungals targeted to the cell wall: focus on I3-1,3-glucan synthase inhibitors. Expert Opin Investig. Drugs (2001) 10:269–280.
  • ••Excellent update on the glucan synthaseand chitin synthase inhibitors.
  • KEATING GM, JARVIS B: Caspofungin. Drugs (2001) 61:1121–1129.
  • BARTIZAL K, GILL CJ, ABRUZZO GK et al.: In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother (1997) 41:2326–2332.
  • VAZQUEZ JA, LYNCH M, BOUKOV D, SOBEL JD: hi vitro activity of new pneumocandin antifungal L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob. Agents Chemother (1997) 41:1612–1614.
  • PFALLER MA, MESSER SA, GEES et al.: In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents.. Microbial. (1999) 37:870–872.
  • DEL POETA M, SCHELL WA, PERFECT JR: In vitro antifungal activity of Pneumocandin L-743, 872 against a variety of clinical important molds. Antimicrob. Agents Chemother (1997) 41:1835–1836.
  • GONZALEZ GM, TIJERINA R, NAJ VAR LK et al.: Correlation between antifungal susceptibilities of Coccidiaides immitis in vitro and antifungal treatment with caspofungin in a mouse model. Antimicrob. Agents Chemother. (2001) 45:1854–1859.
  • FRANZOT SP, CASADEVALL A: Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptocaccus neaformaris in vitro. Antimicrob. Agents Chemother (1997) 41:331–336.
  • DEL POETA M, CRUZ MC, CARDENAS ME et al.: Synergistic activities of bafilomycin Al, fluconazole and the pneumocandin MK-099 1 /caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus rieoformaris. Antimicrob. Agents Chemother. (2000) 44:739–746.
  • HEITMAN J, MOVVA NR, HIESTAND PC, HALL MN; FK 506-binding protein proline rotamase is a target for the immunosuppressive agent FK 506 in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA (1991) 88:1948–1952.
  • CHILLER T, FARROKHSHAD K, BRUMMER E, STEVENS DA: Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatus. Aritimicrob. Agents Chemother (2000) 44:3302–3305.
  • CHILLER T, FARROKHSHAD K, BRUMMER E, STEVENS DA: The interaction of human monocytes, monocyte-derived macrophages and polymorphonuclear neutrophils with caspofungin (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus. Diagri. Microbial. Infect. D (2001) 39:99–103.
  • HADJU R, THOMPSON R, JG et al.: Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob. Agents Chemother. (1997) 41:2339–2344.
  • GROLL AH, GULLICK BM, R et al.: Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits. Antimicrob. Agents Chemother. (2001) 45:596–600.
  • ABRUZZO GK, FLATTERY AM, GILL CJ et al.: Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis and cryptococcosis. Antimicrob. Agents Chemother. (1997) 41:2333–2338.
  • GRAYBILL JR, NAJVAR LK, LUTHER MF, FOTHERGILL AW: Treatment of murine disseminated candidiasis with L-743, 872. Antimicrob. Agents Chemother (1997) 41:1775–1777.
  • GRAYBILL JR, BOCANEGRA R, LUTHER M, FOTHERGILL A, RINALDI MJ: Treatment of murine Caridida krusei or Caridida glabrata infection with L-743,872. Antimicrob. Agents Chemother (1997) 41:1937–1939.
  • ABRUZZO GK, GILL CJ, FLATTERY AM et al.: Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob. Agents Chemother (2000) 44:2310–2318.
  • BOWMAN JC, ABRUZZO GK, ANDERSON JW et al.: Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob. Agents Chemother (2001) 45:3474–3481.
  • GRAYBILL JR, NAJVAR LK, MONTALBO EM, BARCHIESI FJ, LUTHER MF, RINALDI MO: Treatment of histoplasmosis with MK-0991 (L-743, 872). Antimicrob. Agents Chemother. (1998) 42:151–153.
  • KOHLER S, WHEAT LJ, CONNOLLY P etal.: Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model. Antimicrob. Agents Chemother (2000) 44:1850–1854.
  • POWLES MA, LIBERATOR E ANDERSON J et al.: Efficacy of MK991 (L-743,872), a semisynthetic pneumocandin, in murine models of Prieumocystis carinli. Antimicrob. Agents Chemother (1998) 42:1985–1989.
  • BALANI SK, XU X, ARISON BH et al.:Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug. Metab. Dispos. (2000) 28:1274–1278.
  • SABLE CA, VILLANUEVA A, E et al.: A randomised, double blind multicenter trial of MK-991 (L-743,872) vs. amphotericin B in the treatment of Caridida esophagitis in adults. 37th Iriterscierice Conference on Antimicrobial Agents and Chemotherapy (1997) Abstract No. LB–33.
  • NILIUS AM, RANEY PM, HENSEY-RUDLOFF DM, WANG W, LI Q, FLAMM RK: In vitro activity of A-192411.29, a novel antifungal lipopeptide. Antimicrob. Agents Chemother (2000) 44:1242–1246.
  • GUNAWARDANA G, RASMUSSEN RR, SCHERR M et al.: Corynecandin: a novel antifungal glycolipid from Coryrieum modonium: j Aritibiot. (Tokyo) (1997) 50:884–886.
  • HAWSERS, BORGONOVI M, MARKUS A, ISERT D: Mulundocandin, an echinocandin-like lipopeptide antifungal agent: biological activities in vitro. Aritibiot. (Tokyo) (1999) 52:305–310.
  • HAWSER S, ISLAM K: Comparisons of the effects of fungicidal and fungistatic antifungal agents on the morphogenetic transformation of Caridida albicaris. Antimicrob. Chemother. (1999) 43:411–413.
  • DOUGLAS CM, FOOR E MARRINAN JA et al.: The Saccharomyces cerevisiae FKS1 (ETC1) gene encodes an integral membrane protein which is a subunit of 1,3-I3-D-glucan synthase. Proc. Natl. Acad. Sci. USA (1994) 91:12907–12911.
  • MAZUR P, MORIN N, BAGINSKY W et al.: Differential expression and function of two homologous subunits of yeast 1,3-I3-D-glucan synthase. Mol. Cell Biol. (1995) 15:5671–5681.
  • MAZUR P, BAGINSKY W: In vitro activityof 1,3-13-D-glucan synthase requires the GTP-binding protein Rho 1. j Biol. Chem. (1996) 211:14604–14609.
  • INOUE SB, QADOTA H, ARISAWA M, WATANABE T, OHYA Y: Prenylation of Rho lp is required for activation of yeast 1,3- P-D-glucan synthase. j Biol. Chem. (1999) 274:38119–38124.
  • •Excellent paper on the geranylisation of Rholp.
  • MIO T, SHIMIZU MA, TACHIBANA Y et al.: Cloning of the Candida albicaris homologue of Saccharomyces cerevisiae CSCII FKS1 and its involvement in 1,3-13-D-glucan synthesis. j Bacteria. (1997) 179:4096–4105.
  • DOUGLAS CM, D'IPPOLITO JA, SHEI GJ et al.: Identification of the FKS1 gene of Caridida albicaris as the essential target of 1,3 13 D glucan synthase inhibitors. Aritimicrob. Agents Chemother. (1997) 41:2471–2479.
  • KOTTOM TJ, LIMPER AH: Cell wall assembly by Prieumocystis caririii. Evidence for a uinique Gsc-1 subunit mediating 1,3-3-D-glucan deposition. j Biol. Chem. (2000) 275:40628–40634.
  • THOMPSON JR, DOUGLAS CM, LI W et al.: A glucan synthase FKS1 homolog in Cryptococcus rieoformaris is single copy and encodes an essential function. j Bacterial. (1999) 181:444–453.
  • •Important paper on glucan synthase of C. neoformans.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.